Administration of platelet concentrates suspended in bicarbonated Ringer's solution in children who had platelet transfusion reactions

Kobayashi, Jun; Yanagisawa, Ryu; Ono, Toshiaki; Tatsuzawa, Yuka; Tokutake, Yumi; Kubota, Noriko; Hidaka, Eiko; Sakashita, Kazuo; Kojima, Shunsuke; Shimodaira, Shigetaka; Nakamura, Tomohiko

doi:10.1111/vox.12608

Cited by 13 publications

(39 citation statements)

References 32 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, during this study period, both LR products and non‐LR existed. If a patient presented with a TRAR, washed products were prepared according to the number of TRARs or the severity of the reaction . In the guidelines of the Japan Society of Transfusion Medicine and Cell Therapy, introduction of washed PLT concentrates is recommended when TRARs occur more than twice despite premedication.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of clinical presentations of allergic transfusion reactions and febrile non‐haemolytic transfusion reactions in paediatric patients

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background and objectives Like adults, children can have allergic transfusion reactions (ATRs) and febrile non-haemolytic transfusion reactions (FNHTRs). But published information about the incidence of paediatric ATR and FNHTR is scarce.Materials and methods This retrospective study was conducted from April 2002 to June 2018 on children who had ATRs and/or FNHTRs to platelet (PLT), red blood cell (RBC) or washed PLT/RBC concentrate transfusions. We analysed ATR/ FNHTR clinical presentations, such as severity, time of occurrence and other features when they occurred.Results During the study, 2742 children received 23 444 bags of PLT and RBC concentrate (including washed products). ATRs occurred in 100 cases (3Á6% of total patients), caused by 201 products (0Á9% of total products). In contrast, 28 patients (1Á0% of total patients) had 42 FNHTRs caused by 42 products (0Á2% of total products). Upon analysis of cases with detailed clinical information, the median onset time for ATRs and FNHTRs was 2Á0 h after the start of transfusion. Of the 40% of ATRs that necessitated the discontinuation of blood transfusions, 10% escalated to anaphylaxis. Compared with minor ATRs, anaphylaxis tended to develop quickly. Moreover, 96% of patients with FNHTRs had a fever less than 39°C. There were no associations between blood product types and numbers or occurrence patterns of these reactions. ConclusionThe occurrence of ATRs and FNHTRs in children was variable, although there are common features such as severity and time of occurrence.

show abstract

Section: Methodsmentioning

confidence: 99%

“…For ATRs, at least one symptom, such as rash, pruritus, urticaria, flushing and respiratory distress, occurred during transfusion or within 4 h of its end. . The severity of each ATR was defined per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 .…”

Section: Methodsmentioning

confidence: 99%

Analysis of clinical presentations of allergic transfusion reactions and febrile non‐haemolytic transfusion reactions in paediatric patients

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The effectiveness of washed platelet concentrate (PC) in reducing adverse reactions associated with PC transfusion, including allergic transfusion reactions (ATRs), has been clarified in previous reports . Good platelet additive solutions (PASs) are essential for washing platelets .…”

mentioning

confidence: 99%

“…It was recently reported that M‐sol and BRS‐A can be used in succession as PASs . In Japan, these solutions are prepared by mixing commercially available products, and their clinical application is currently being tested . M‐sol requires a mixture of five kinds of commercially available solutions and can be preserved for 1 year using a special method .…”

mentioning

confidence: 99%

“…In Japan, these solutions are prepared by mixing commercially available products, and their clinical application is currently being tested . M‐sol requires a mixture of five kinds of commercially available solutions and can be preserved for 1 year using a special method . Conversely, BRS‐A has the advantage of being easily adjusted by mixing two bicarbonated Ringer solutions with ACD‐A solution .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of administration of platelet concentrates suspended in M‐sol or BRS‐A for pediatric patients

et al. 2018

View full text Add to dashboard Cite

BACKGROUND Two different platelet additive solutions (PASs), M‐sol and BRS‐A, used in succession, have been reported as novel PASs in Japan. However, there are not enough clinical data comparing platelet concentrates (PCs) suspended in these PASs. STUDY DESIGN AND METHODS A retrospective cohort study of consecutive cases was performed between 2013 and 2018. For the first 30 months, children with primary hematologic and/or malignant diseases were transfused resuspended PCs in M‐sol (RPC‐M) as plasma‐replaced PCs. For the subsequent 30 months, children were transfused plasma‐replaced PCs in BRS‐A (RPC‐B) under the same conditions. Children transfused with conventional PCs (containing residual plasma) were defined as controls. We evaluated the frequency of adverse events, corrected count increment (CCI), and bleeding occurrence in the children. RESULTS Overall, 84 patients received 679 conventional PC transfusions. Allergic transfusion reactions (ATRs) occurred in 12 (14.3%) patients transfused with 12 (1.8%) bags. Fifty‐nine patients received a total of 1182 bags of RPC‐M, and one patient (1.7%) had five (0.4%) ATR episodes. During the last 30 months, 58 patients were transfused 1044 bags of RPC‐B, with ATRs occurring in four (6.9%) patients transfused with four (0.4%) bags. No other adverse events were observed with either RPC‐M or RPC‐B. CCIs (24 hr) were not significantly different for the three different PCs, and posttransfusion bleeding was not observed. CONCLUSIONS Plasma‐replaced PC using two different PAS in children appeared to prevent ATRs accompanied without other adverse events in children. Transfusion efficacy was not significant; therefore, either of the PASs could be used with equivalent results based on the clinical situation.

show abstract

Platelet transfusion in adults: An update

Garraud

Hamzeh‐Cognasse²,

Chalayer³

et al. 2023

Transfusion Clinique et Biologique

View full text Add to dashboard Cite

Administration of platelet concentrates suspended in bicarbonated Ringer's solution in children who had platelet transfusion reactions

Abstract: Washed PCs containing BRS-A appear to prevent ATRs without loss of transfusion efficacy in children with primary haematological and malignant diseases. Their efficacy should be further evaluated through larger prospective clinical trials.

Cited by 13 publications

References 32 publications

Analysis of clinical presentations of allergic transfusion reactions and febrile non‐haemolytic transfusion reactions in paediatric patients

Analysis of clinical presentations of allergic transfusion reactions and febrile non‐haemolytic transfusion reactions in paediatric patients

Comparison of administration of platelet concentrates suspended in M‐sol or BRS‐A for pediatric patients

Platelet transfusion in adults: An update

Contact Info

Product

Resources

About